From 13 till 16 June 2024: HIGHLIGHTS ON HEMATOLOGY
Your direct line with Madrid
From 13 till 16 June 2024, The European Hematology Association (EHA) is taking place in Madrid, Spain. The MediMix team is onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen.
And, we also dive into posters and hot topics with both Belgian and international experts.
Stay tuned!
With the educational support of:
Daily highlights
In this video, Prof Dr Claudio Cerchione, haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy shares his congress highlights from EHA 2024 in the field
In this video, Dr Fabio Andreozzi, haematologist at the Institut Jules Bordet in Brussels, discusses the key highlights from EHA 2024 in the field of acute myeloid leukaemia (AML)
Within
In this video, Dr Adriano Salaroli, haematologist at the Institut Jules Bordet in Brussels, shares his congress highlights from EHA 2024.
For patients with chronic myeloid leukaemia (CML), the most
In this video, Dr Rutger Callens, haematologist at the AZ Delta hospital in Roeselare, talks us through the highlights of the oral abstract session at EHA 2024 discussing innovations in
In this video, Prof EM Dominique Bron, haematologist at the Jules Bordet Institute in Brussels provides us with a helicopter view of the contemporary treatment landscape for patients with chronic
In-depth stories
Dr Lucia Perez-Lamas, a haematologist at the Puerta de Hierro University Hospital in Madrid, Spain, presented real-world evidence on the use of momelotinib in myelofibrosis (MF) patients with anaemia.
Dr Adriano Salaroli, a haematologist at the Institut Jules Bordet in Brussels, provides an update on cytopenic myelofibrosis, emphasising the need for increased awareness regarding this specific subtype of myelofibrosis.
Dr Marie Vercruyssen, a haematologist at the Institut Jules Bordet in Brussels, summarised the outcomes of the IMROZ trial, which evaluated the addition of the anti-CD38 monoclonal antibody isatuximab to
Dr Sigrún Thorsteinsdóttir, a haematologist at Rigshospitalet in Copenhagen, Denmark, also holds a position as a postdoctoral researcher in the iStopMM study at the University of Iceland. The iSTOPMM study
Dr Hanne Norseth, a haematologist at the Oslo Myeloma Center in Norway, presented the results of the phase I/II TG01 study. This study evaluates the safety and efficacy of the
At the EHA 2024 conference, Prof Dr Xavier Leleu, Head of the Myeloma Clinic and Department of Haematology at the University Hospital of Poitiers (France), presented the results of the
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, highlights the necessity for novel treatment combinations in lenalidomide-refractory MM patients. Belantamab
During EHA 2024, an entire session was dedicated to the management of difficult to treat multiple myeloma (MM) populations. In this session, Dr Claudia Stege, haematologist at the Erasmus Medical
During EHA 2024, Dr Anita Rijneveld, haematologist at the Erasmus Medical Center Cancer Institute in Rotterdam, presented the final results of the phase II HOVON-146 study. This study evaluated the
During EHA 2024, Prof Dr Xavier Leleu, Head of the Myeloma Clinic and Head of the Department of Haematology at the University Hospital of Poitiers (France), presented the results of
Prof Dr Giovanni Martinelli, a haematologist at the “L. e A. Seragnoli” Institute in Bologna, Italy, presented Impact-AML, a European master framework designed for cohort studies and pragmatic clinical trials
In this video, Prof Dr Selina Luger, haemato-oncologist at the hospital of the University of Pennsylvania discusses the recent changes in the treatment landscape for adult patients with acute lymphoblastic
Prof Dr Nathalie Meuleman, haematologist at the Institut Jules Bordet in Brussels summarized the outcomes of the BENEFIT trial presented at EHA 2024
CD38-targeting immunotherapy, in combination with lenalidomide and
Dr Fredrik Schjesvold, director of the Oslo Myeloma Center at the Oslo University Hospital in Norway, previously discussed the randomized phase III GMMG-HD7 study which showed that the addition of
Prof Timothy Devos, a haematologist at UZ Leuven, chaired a session on myeloproliferative neoplasms (MPN) organised by the specialised working group of the EHA. He provided a comprehensive summary of
Poster selection
Dr Yana Stepanishyna, a haematologist at the Institut Jules Bordet in Brussels, presents a preliminary analysis from the SOPRALLO project.
Allogeneic hematopoietic stem cell transplantation (HSCT) has significantly extended the
Epcoritamab (EPCOR) is a novel, subcutaneous CD3xCD20 bispecific antibody (bsAb) that has demonstrated deep and durable responses with manageable safety in patients with R/R FL following at least two systemic
Wouter Sleeckx, a doctoral researcher at the University of Ghent, presented his research on the therapeutic potential of targeting the IL-4 signalling pathway in a subset of T-ALL patients. His
Cristina Borin, a doctoral researcher at the University of Ghent and the Cancer Research Institute Ghent (CRIG) presented her work on the functional characterization of Kdm6b in immature leukemia. Her
Dr Yvan Momo, a haematologist at the Hopital Universitaire de Bruxelles in Brussels, presents an analysis of transfusion practices in a Belgian sickle cell reference centre, assessing their adherence to
The current standard treatment for R/R cHL involves salvage chemotherapy followed by ASCT. However, the optimal salvage therapy regimen remains undefined. Recent evidence suggests that the combination of brentuximab vedotin
Thomas Slegers, a doctoral researcher, and Dr Marlies Vanden Bempt, a postdoctoral researcher, both from KU Leuven, presented their research on the dual targeting of EZH2 and HDAC in haematological
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, shares insights from the PREAMBLE registry. This registry documents treatment patterns and
Dr Pau Montesinos, a haematologist at the Hospital Universitario y Politècnico La Fe in Valencia, Spain, presented a post hoc analysis of the phase 3 QuANTUM-First study. This analysis evaluated